Research Article| Volume 17, ISSUE 1, P52-59, January 1995

Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a)

      This paper is only available as a PDF. To read, Please Download here.


      The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 out-patients who had serum Lp(a) levels higher than 20 mg/dL. The mean (±SE) levels of Lp(a) decreased from 33.6 ± 2.3 mg/dL to 23.5 ± 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apoliprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Berk K
        A new serum type system in man: The L'p system.
        Acta Pathol Microbiol Scand. 1963; 59: 369-382
        • Dahlen GH
        • Guyton JR
        • After M
        • et al.
        Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with artery disease documented by angiography.
        Circulation. 1986; 74: 758-765
        • Hoefler G
        • Harnoncourt F
        • Paschke E
        • et al.
        Lipoprotein Lp(a): A risk factor for myocardial infarction.
        Arteriosclerosis. 1988; 8: 398-401
        • Genest Jr, J
        • Jenner JL
        • McNamara JR
        • et al.
        Prevalence of lipoprotein(a) (Lp[a]) excess in coronary artery disease.
        Am J Cardiol. 1991; 67: 1039-1045
        • Rosengren A
        • Wilhelmsen L
        • Eriksson E
        • et al.
        Lipoprotein(a) and coronary heart disease: A prospective case control study in a general population sample of middle-aged men.
        BMJ. 1990; 301: 1248-1251
        • Genest Jr, J
        • McNamara JR
        • Ordovas JM
        • et al.
        Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein(a) abnormalities in men with premature coronary artery disease.
        J Am Coll Cordiol. 1992; 19: 792-802
        • Zenker G
        • Költtringer P
        • Bone G
        • et al.
        Lipoprotein(a) as a strong indicator for cerebrovascular disease.
        Stroke. 1986; 17: 942-945
        • Murai A
        • Miyahara T
        • Fujimoto N
        • et al.
        Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction.
        Atherosclerosis. 1986; 59: 199-204
        • McLean JW
        • Tomlinson JE
        • Kuang WJ
        • et al.
        cDNA sequence of human apolipoprotein(a) is homologous to plasminogen.
        Nature. 1987; 330: 132-137
        • Hajjar KA
        • Gavish D
        • Breslow JL
        • Nachman RL
        Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.
        Nature. 1989; 339: 303-305
        • Carlson LA
        • Orö L
        • Östman J
        Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia.
        Acta Med Scand. 1968; 183: 457-465
        • Curtis LD
        • Reckless JP
        • Winder AF
        • Betteridge DJ
        Clinical and laboratory responses to niceritrol in the treatment of hypercholesterolaemia.
        Postgrad Med J. 1989; 64: 672-675
        • Ho LT
        • Chern JC
        • Hsu SC
        • et al.
        The antilipemic effectiveness of pentaerythritol tetranicotinate on hyperlipidemic patients with or without diabetes mellitus—a double-blind, randomized and two-period change-over experiment.
        Proc Natl Sci Counc Repub China [B]. 1985; 9: 20-29
        • Hamazaki T
        • Hamazaki T
        • Hasunuma K
        • Kobayashi S
        • et al.
        The effects on lipids, blood viscosity and platelet aggregation of combined use of niceritrol (Perycit) and a low dose of acetylsalicylic acid.
        Atherosclerosis. 1985; 55: 107-113
        • Eklund B
        • Kaijser L
        • Nowak J
        • Wenmalm A
        Prostaglandins contribute to the vasodilatation induced by nicotinic acid.
        Prostaglandins. 1979; 17: 821-830
        • Yamaguchi H
        • Lee YJ
        • Daida H
        • et al.
        Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty: LDL-apheresis angioplasty restenosis trial.
        Chem Phys Lipids. 1994; 67–68: 399-403
        • Sano R
        • Fujino A
        • Saito T
        • et al.
        Reduction by niceritrol treatment of serum lipoprotein(a) in normolipidemic patients.
        Tohoku J Exp Med. 1993; 169: 229-307
        • Nakahama H
        • Nakanishi T
        • Uyama O
        • et al.
        Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.
        Renal Fail. 1993; 15: 189-193
        • Matsunaga A
        • Handa K
        • Mori T
        • et al.
        Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.
        Arteriosclerosis. 1992; 94: 241-248
        • Abe A
        • Yoshimura Y
        • Sekine T
        • et al.
        Fully mechanized latex immunoassay for serum lipoprotein(a).
        Clin Chim Acta. 1994; 225: 105-113
        • Clauss A
        Gerinnungsphysiologische Schnell-methode zur Bestimmung des Fibrinogens.
        Acta Haematol. 1957; 17: 237-246
        • Friberger P
        • Knos M
        • Gustavsson S
        • et al.
        Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251.
        Haemostasis. 1978; 7: 138-145
        • Declerck PJ
        • Alessi MC
        • Verstreken M
        • et al.
        Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.
        Blood. 1988; 71: 220-225
        • Bergsdorf N
        • Nilsson T
        • Wall'en P
        An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease.
        Thromb Haemost. 1983; 50: 740-744
        • Kodama S
        • Uchijima E
        • Nagai M
        • et al.
        One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies.
        Clin Chim Acta. 1990; 192: 191-199
        • Carlson LA
        • Hamsten A
        • Asplund A
        Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.
        J Intern Med. 1989; 226: 271-276
        • Meade TW
        • Chakrabarti R
        • Heines AP
        • et al.
        Haemostatic function and cardiovascular death: Early results of a prospective study.
        Lancet. 1980; 1: 1050-1054
        • Kannel WB
        New perspectives on cardiovascular risk factors.
        Am Heart J. 1987; 114: 213-219